Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578420 | 0.85 | SMN1; SMN2 (0.82) | SMN1; SMN2KMT2ATSHRMEN1CYP3A4 | |
| SCHEMBL23929061 | 0.85 | SMN1; SMN2 (0.82) | SMN1; SMN2KMT2ATSHRMEN1CYP3A4 | |
| SCHEMBL5840443 | 0.85 | SMN1; SMN2 (0.75) | SMN1; SMN2KMT2ATSHRMEN1CYP3A4 | |
| SCHEMBL8616990 | 0.84 | SMN1; SMN2 (0.79) | SMN1; SMN2KMT2ATSHRMEN1CYP3A4 | |
| SCHEMBL4578093 | 0.82 | ALDH1A1 (0.70) | SMN1; SMN2KMT2ATSHRMEN1CYP3A4 | |
| SCHEMBL4579798 | 0.82 | ALDH1A1 (0.77) | SMN1; SMN2TSHRHTTALDH1A1KDM4E | |
| SCHEMBL29070246 | 0.82 | HSD17B10 (0.68) | SMN1; SMN2KMT2AMEN1CYP2C19ALDH1A1 | |
| SCHEMBL5840433 | 0.81 | SMN1; SMN2 (0.75) | SMN1; SMN2KMT2ATSHRMEN1CYP3A4 | |
| SCHEMBL2929473 | 0.81 | ALDH1A1 (0.81) | SMN1; SMN2KMT2ATSHRMEN1HTT | |
| SCHEMBL17937106 | 0.80 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2ATSHRMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | claimed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | claimed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | claimed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | claimed |
| US-11325940-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325940-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | SMN1; SMN2 3577/4885KMT2A 2329/4885TSHR 4621/4885 |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | SMN1; SMN2 3956/4885KMT2A 1033/4885TSHR 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.